About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, March 2nd, 2015

The QualityStocks
Daily Stock List


AmpliPhi Biosciences Corp. (APHB)

Wallstreetlivechat and StreetInsider reported earlier on AmpliPhi Biosciences Corp. (APHB), and we report on the Company today, here at the QualityStocks Daily Newsletter.

AmpliPhi Biosciences Corp. is a biotechnology company and the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections. Its product development programs target infections that are often resistant to existing antibiotic treatments. OTCQB-listed AmpliPhi Biosciences has its headquarters in Richmond, Virginia. The Company has operations outside Sydney, Australia.

AmpliPhi Biosciences centers on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Bacteriophages, or “eaters of bacteria,” are highly targeted viruses. They only infect bacteria. As they grow, many bacteriophages destroy their bacterial host to release hundreds of new bacteriophages.  

Phage-based therapy provides an innovative and proven approach to treating a wide assortment of bacterial infections and more precisely, drug-resistant strains of bacteria that are normally found in hospitals. AmpliPhi Biosciences is the first company to demonstrate the clinical efficacy of phage technology in a controlled, regulated, human clinical trial.

The Company has focused initially on controlling one particular problem, namely “Pseudomonas aeruginosa” infections. Pseudomonas aeruginosa is a common soil organism. It is responsible for long-term problems in humans, infecting burns, wounds, and body cavities. Its product development pathway includes AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by P. aeruginosa; AmpliPhage-002: Wound and Skin Infections Caused by S. aureus; and AmpliPhage-004; Gastrointestinal (GI) Infection Caused by C. difficile infection (CDI).

AmpliPhi Biosciences is working together with a number of top organizations to quickly advance bacteriophage-based therapies. These organizations include Intrexon Corp. (XON), the U.S. Army, and UK-based University of Leicester. AmpliPhi’s proprietary technology has additional applications for the treatment of a broad assortment of serious infections. The Company has a new and first-in-class GMP-ready bacteriophage production facility now fully operational in Slovenia.

AmpliPhi Biosciences continues to focus on continuing strategic R&D initiatives with leading industry, academic, as well as government partners in Europe, Australia, and the United States. At first, AmpliPhi’s phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

This past January, AmpliPhi Biosciences provided a shareholders update. The update confirmed that the Company is on course to enter human clinical trials in the second half of this year with an optimized bacteriophage product targeting multi-drug resistant Staphylococcus aureus. AmpliPhi further reported it is preparing for an up-listing to a major stock exchange.

AmpliPhi Biosciences and University of Leicester are developing a panel of C. difficile bacteriophages as a targeted treatment against C. difficile infection. During this year, AmpliPhi and University of Leicester will continue nonclinical product optimization. This includes phage and host production optimization, formulation development and finalization, as well as potential combination therapies with antibiotics. These efforts will prepare the product for entry into human clinical studies in 2016.

AmpliPhi Biosciences Corp. (APHB), closed Monday's trading session at $0.195, even for the day, on 759,845 volume with 83 trades. The average volume for the last 60 days is 274,817 and the stock's 52-week low/high is $0.07/$0.62.

Bioheart, Inc. (BHRT)

PennyStocks24, Pennybuster, Energy and Capital, and SmallCapVoice reported on Bioheart, Inc. (BHRT), and today we highlight Company, here at the QualityStocks Daily Newsletter.

Bioheart, Inc.’s dedication is to maintaining its leading position within the cardiovascular sector of the cell technology industry. The Company delivers cell therapies and biologics. These help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, as well as other issues. Its lead product is MyoCell®. Its MyoCell® product is a clinical muscle-derived cell therapy. Bioheart is based in Sunrise, Florida.

The Company’s objectives are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and lower health care costs and hospitalizations. Regarding biotechnology, it is concentrating on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease.

The design of Bioheart’s MyoCell® is to populate regions of scar tissue within a patient's heart with new living cells to improve cardiac function in chronic heart failure patients. The Company’s MyoCell® therapy consists of myoblasts, which are injected into the scar tissue that has formed in the hearts of patients suffering from heart failure. The increased muscle formed by MyoCell® in these patients’ hearts has been shown to lead to improved cardiac function and an improved quality of life. MyoCell® may help to promote myogenesis or new muscle formation.

Bioheart’s AdipoCell™ product is presently undergoing study in a variety of indications. These include erectile dysfunction, chronic obstructive pulmonary disease, and dry macular degeneration. Around four years ago, Bioheart commenced a study using adipose derived stem cells (AdipoCell™) in congestive heart failure patients. AdipoCell™ may help to promote angiogenesis or new blood vessel formation in ischemic tissue.

The Company released preliminary 12 month data, in October 2014, from its Phase I ANGEL Trial. Fully funded by Bioheart, the trial is taking place in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). The Phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell™) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months, and 12 months.

In January, Bioheart announced that it will advance its Myocell™ and Myocell™ SDF-1 programs ahead for the treatment of chronic heart failure. The Myocell™ product candidate (called the MARVEL clinical trial) will advance into US FDA phase 3 clinical evaluation for the treatment of chronic heart failure. The re-start of the Myocell™ clinical trial is conditional to re-engagement with the principle investigators and related institutional requirements and internal preparations.

Furthermore, Bioheart announced the diversification of its product development pipeline into the treatment of autoimmune diseases. It plans to evaluate a number of autoimmune disease targets with its Adipocell™ therapy platform. The first will be Rheumatoid Arthritis (RA).

Bioheart, Inc. (BHRT), closed Monday's trading session at $0.0089, down 1.11%, on 3,607,958 volume with 41 trades. The average volume for the last 60 days is 2,331,377 and the stock's 52-week low/high is $0.007/$0.08.

Epazz, Inc. (EPAZ)

Greenbackers, RockingPennyStocks, Pennystocks24, Pennybuster, Actual Gains, PennyStockRumors.net, PricelessPennyStocks, ShazamStocks, and PennyStockPower reported recently on Epazz, Inc. (EPAZ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Epazz, Inc., is a top provider of cloud based business software solutions. The Company's specialty is providing customized cloud applications to the corporate world, higher education institutions, and the public sector. Epazz has created software to enhance the ways institutions and corporations do business.

Shaun Passley founded Epazz in February of 1999. He saw the need and benefits of integrated web-based applications for the growing demand of relevant and timely information for personal and business management The Company lists on the OTC Markets Group’s OTCQB and has its headquarters in Chicago, Illinois.

Epazz’s innovative BoxesOS applications can create virtual communities for enhanced communication, provide information and content for decision-making, as well as create a secure marketplace for any type of commerce all by way of the Internet.

The Company’s Epazz BoxesOS™ v3.0 is a total business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides several of the web-based applications organizations would have to purchase separately. Epazz provides all of the services needed to install BoxesOS. Its programmers will develop custom applications to make sure a business is fully web enabled.

Epazz uses a Virtual Private Server to keep a company's data private and secure. Concerning a Virtual Private Network (VPN), Boxes OS enables an organization to immediately enhance the communication between stakeholders. There is improvement in administrative utility regardless of whether they are on legacy platforms or recent ERP implementations, for example Peoplesoft, Datatel, SCT, Oracle, and SAP. With BoxesOS™ 3.0, an organization can connect multiple databases over VPN.

Epazz announced in November 2014 that it completed the acquisition of Strand, Inc. Strand is a surveillance software company used by U.S. colleges and universities. Strand's surveillance management system is a "lean client" that designates the server for a majority of the data processing.

In January of this year, Epazz announced that it signed a purchase agreement to acquire a Medical Billing Software Company in the Western United States. The expectation is that this new acquisition will provide major growth to the Company’s revenue stream through bringing in $700,000 in revenues in the first year. The unaudited revenues for 2014 were more than $700,000. This is Epazz's largest acquisition so far.

Last week, Epazz confirmed its maintenance contracts renewal rates for Intellisys Software are well in excess of the 95 percent level and is positioned to continue in this manner. Epazz is working on releasing the next version of Cynergy that will integrate with Intellisys SystemVIEW Cloud. Intellisys's New SystemVIEW Cloud has signed more than $50,000 worth of contracts from existing customers in January 2015. The Company is in the process of marketing the new product to new Vertical Markets. SystemVIEW Cloud will open up new revenue streams.

Epazz, Inc. (EPAZ), closed Monday's trading session at $0.0003, down 40.00%, on 72,266,045 volume with 92 trades. The average volume for the last 60 days is 4,611,387 and the stock's 52-week low/high is $0.0003/$11.00.

Medifirst Solutions, Inc. (MFST)

Value Penny Stocks, Wall Street Beauties, WINNINGOTC, FatCat Stocks, PennyStockScholar, PennyStocks24, OTCtipReporter, and Greenbackers reported recently on Medifirst Solutions, Inc. (MFST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifirst Solutions, Inc. looks for ground-breaking medical and healthcare products and technologies targeted to medical and healthcare professionals and everyday consumers. The Company plans to develop and establish a consumer and professional medical base and clientele to be used as a pipeline, which will allow for expansion with new products and services. Medifirst Solutions is based in Freehold, New Jersey.

The Company’s dedication is to provide unique drug free and pain free treatments, services, and products for people to make better and healthier choices and improve their quality of life.  Medifirst is offering its LED Botanical Light Therapy in its Boca Raton, Florida office. Medifirst launched a new Health and Wellness Division, called Medi-First Light Therapy Systems with its new and pioneering LED Botanical Light Therapy Systems.

The Boca Raton location centers on Light Therapy Systems for cosmetic and anti-aging therapy. Medifirst is creating an infrastructure founded on the Botanical Light Therapy Systems and the very positive results it indicates it is attaining. The LED Botanical Light Therapy Systems have not been evaluated by the Food and Drug Administration (FDA).

The Company has completed an agreement with Atmospheric Water Solution, which is a company that generates water through using an advanced patented technology. The water generating machines extract water directly from the air. 

Medifirst Solutions announced in 2014 that it acquired Consumer Resources Consultants, Inc., a company that provides online remote technical support to PC users. The acquisition is part of Medifirst’s plan to increase its internal technology infrastructure and add technical and digital services and expertise to its internal business operations.

Medifirst Solutions also announced in 2014 that it signed an agreement to acquire Florida-based Medical Lasers Manufacturer, Inc. This company has created an innovative Laser Program designed for anti-aging applications.

Medifirst Solutions announced in August 2014 that it agreed in principle to acquire a New Jersey based medical practice. This practice specializes in anti-aging and cosmetic procedures. The practice has multiple locations. The practice has also developed a business model and brand, which includes specific cosmetic services that can be packaged to provide expansion similar to a franchise for additional business development.

Furthermore, Medifirst Solutions has created a unique Program, named The Time Machine Program designed for anti-aging applications, which includes The Full Makeover, Non-Surgical Face Lift, non-invasive restoration & re-surfacing of the skin's tissues and skin tightening. Additional treatments are for sun spots, wrinkles, acne, hyper-pigmentation, scars, skin detoxification, stretch marks, as well as cellulite.

Medifirst Solutions, Inc. (MFST), closed Monday's trading session at $0.03, up 7.14%, on 1,313,550 volume with 58 trades. The average volume for the last 60 days is 180,992 and the stock's 52-week low/high is $0.0206/$0.219.

OXIS International, Inc. (OXIS)

Gryphon Digest, PennyStocks24, TopPennyStockMovers, Equity Observer, Value Penny Stocks, and Real Pennies reported earlier on OXIS International, Inc. (OXIS), and today are reporting on the Company, here at the QualityStocks Daily Newsletter.

Tampa, Florida-headquartered OXIS International, Inc. is a biotechnology company centering on cannabinoid therapy development and commercialization. The OTCQB-listed Company develops and commercializes unique drugs of therapeutic molecules including cannabinoids that are concentrating on several cancer indications. OXIS International’s wholly-owned subsidiary is Oxis Biotech, Inc.

OXIS International addresses the clinical shortcomings of existing commercial products in related fields. It has developed relationships with some of the world's top cannabinoid researchers and institutions to advance its technologies. OXIS’ emphasis is to produce a platform of synthesized cannabinoid agents that target the treatment of cancer cells in multiple areas. The Company will do so using the powerful compounds found in cannabinoid-producing plants.

OXIS announced recently that wholly-owned subsidiary Oxis Biotech executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma. Oxis Biotech also initiated a consulting agreement with University of Pittsburgh's Professor, Dr. Xiang-Qun (Sean) Xie. The license agreement provides Oxis Biotech an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma. Dr. Xie joins Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech.

Moreover, in January, OXIS International announced that Dr. James J. Mulé joined the Scientific Advisory Board for the Company’s wholly-owned subsidiary, Oxis Biotech. Dr. Mulé, Ph.D. currently serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.

OXIS International has its new worldwide exclusive Patent Licensing of "P62 Chemical Agents and Multiple Myeloma Therapeutics", with Dr. Xiang-Qun (Sean) Xie. Dr. Xie, MD, PhD, EMBA is one of the world's leading cannabinoid research scientists. With the inclusion of its P62 Multiple Myeloma Therapeutics platform, the Company is positioned to be a major player in the large and expanding market for Myeloma Therapeutic drug therapies. OXIS International’s focus for this year is to continue to make significant progress with Oxis Biotech, Inc. through adding additional high value patents and assets to its portfolio over the very near future.

OXIS International, Inc. (OXIS), closed Monday's trading session at $0.0315, up 34.27%, on 8,481,750 volume with 355 trades. The average volume for the last 60 days is 1,673,196 and the stock's 52-week low/high is $0.0032/$0.0399.

Tauriga Sciences, Inc. (TAUG)

TheMicrocapNews, Greenbackers, Wallstreetlivechat, PennyStocks Forever, Stock Tips Network, Stock Analyzer, PennyStocks24, Xtremepicks, Penny Stock Rumble, OurHotStockTips, and Xtremepicks reported on Tauriga Sciences, Inc. (TAUG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tauriga Sciences, Inc. is a diversified life sciences company centering on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. Its business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Additionally, the Company has its acquisition in the cannabis space. The Company formerly went by the name Immunovative, Inc. It changed its corporate name to Tauriga Sciences, Inc. in March of 2013.
Tauriga Sciences announced, on January 28, 2014, that it completed the acquisition of Cincinnati, Ohio-based synthetic biology pioneer Pilus Energy, LLC. Pilus Energy is now a wholly-owned subsidiary of Tauriga Sciences. Pilus maintains its headquarters location in Ohio. Subsidiary Pilus Energy is a developer of alternative cleantech energy platforms employing proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater.

In the process, the technology generates electricity and produces economically important gases and chemicals. Pilus Energy licenses a low-cost, scalable electrogenic bioreactor platform and wastewater-to-value BactoBots. Pilus Energy will also gain added revenues from carbon and renewable energy credits (REC).

Tauriga Sciences has been working to establish an international presence through partnerships and global exclusive licenses. This is because its proprietary BactoBot technology can potentially address many global water related issues.

The Company announced in May 2014 that it entered into its first retail distribution agreement for its new line of natural medicine products. The Company’s natural medicine product line includes non-cannabis containing candies, gums, and supplements with proprietary formulations designed to address unwanted cannabis-related effects. Tauriga has launched Cannabis Complements, which is its line of natural dietary supplements that address cannabis-related effects but that do not contain cannabis oil.

Tauriga announced in July 2014 that it completed its acquisition of California-based medicinal cannabis firm Honeywood LLC. Honeywood is the formulator for Doc Green's topical cannabis cream and other products. Subsequently, in September 2014, Tauriga announced the restructuring of its acquisition of Honeywood into a License and Supply Agreement that provides Tauriga Sciences access to the Doc Green's topical cannabis cream and future products.

Last week, Tauriga Sciences announced that it has manufactured its CannaCaviar line of cannabidiol (CBD) soft gels.  CannaCaviar is its second product that uses cannabidiol (CBD) oil extracted from non-GMO industrial hemp as its main ingredient. Moreover, Tauriga sells TopiCanna, a proprietary topical medicinal cannabis cream. The Company says that many who have used topical cannabis creams have reported decreased musculoskeletal pain. The design of TopiCanna and CannaCaviar are to provide potential natural wellness and healing properties without psychoactive effects.

Tauriga Sciences, Inc. (TAUG), closed Monday's trading session at $0.0125, down 10.71%, on 5,058,250 volume with 107 trades. The average volume for the last 60 days is 2,533,192 and the stock's 52-week low/high is $0.0088/$0.1075.

Titan Pharmaceuticals, Inc. (TTNP)

PennyTrader, OTCtipReporter, PennyStocks24, Penny Pick Finders, PennyStockProphet, SecretStockPromo, StockOnion, Planet Penny Stocks, Buzz Stocks, and SmarTrend Newsletters reported on Titan Pharmaceuticals, Inc. (TTNP), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company whose shares trade on the OTC Bulletin Board. The Company is developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. Its principal asset is Probuphine®. This product is the first slow-release implant formulation of buprenorphine hydrochloride (buprenorphine). Titan Pharmaceuticals has its corporate headquarters in South San Francisco, California.

Probuphine® is the first product to utilize ProNeura™ - a novel, proprietary, long-term drug delivery technology. The ProNeura™ technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. The Probuphine New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in October 2012, seeking approval for the treatment of opioid dependence.

The design of Probuphine® is to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. In 2011, a seven-day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the United States.

Probuphine® is an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. The Company’s aim is to enter into one or more collaborations with capable pharmaceutical companies to commercialize Probuphine® in the U.S. and international markets, and to develop, potentially, the product for the treatment of chronic pain.

Titan Pharmaceuticals is also entitled to royalty revenue of 8-10 percent of net sales of Fanapt® (iloperidone). This is an atypical antipsychotic compound being marketed in the United States for the treatment of schizophrenia by Novartis Pharma AG under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension).

Titan Pharmaceuticals announced this past November completion of enrollment in the ongoing Phase 3 study of Probuphine®, the Company’s investigational subdermal implant for the maintenance treatment of opioid dependence. Titan Pharmaceuticals’ partner, Braeburn Pharmaceuticals, is sponsoring the study. The expectation is that study completion will be on schedule by the middle of this year, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. FDA later this year.

Titan Pharmaceuticals, Inc. (TTNP), closed Monday's trading session at $0.6749, up 4.80%, on 1,302,545 volume with 311 trades. The average volume for the last 60 days is 368,632 and the stock's 52-week low/high is $0.44/$0.865.


The QualityStocks
Company Corner


IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.37, off by 7.04%, on 744,401 volume with 183 trades. The stock’s average daily volume over the past 60 days is 660,963, and its 52-week low/high is $0.0114/$1.01.

IFAN Financial, Inc. was pleased to announce that two significant milestones have been achieved by its iPIN Technologies subsidiary under the Company's license agreement. These milestones involve posting the status of a financial transaction to the merchant call back uniform resource locator (URL) and developing the front-end database to enable a merchant processing transaction.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial Reaches Technology Development Milestones

IFAN Financial, Inc. Announces Stock-Based Compensation Plan

IFAN Financial, Inc. Announces the Launch of New Website and Investor Relations Kit

Pure Hospitality Solutions, Inc. (PNOW)

The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.0109, off by 15.50%, on 875,557 volume with 28 trades. The stock’s average daily volume over the past 60 days is 166,225, and its 52-week low/high is $0.0031/$0.8824.

Pure Hospitality Solutions, Inc. announced today, that the Company and Oveedia's development partners, have released initial projections to private investment groups, conservatively placing valuations at amounts anticipated to exceed $40M, relatively shortly thereafter Oveedia's launch. Both management and Pure's development partners, along with the project's consultancy team, have aggressively begun communicating with players in the financial community, for access to the right capital, from the most appropriate investors, to expedite the project's launch.

Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Pure has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Pure Hospitality Solutions, Inc. Company Blog

Pure Hospitality Solutions, Inc. News:

Pure Hospitality anticipates $40 Million Oveedia Valuation with Divest and Focus Strategy

Pure Hospitality Solutions' Value Proposition Increases: Next Oveedia Funding Round Initiated

Pure Hospitality Solutions Increases Focus On Partnerships to Develop Oveedia

Boreal Water Collection, Inc. (BRWC)

The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.0025, up 13.64%, on 2,120,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 862,344, and its 52-week low/high is $0.002/$0.03.

Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!

Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.

Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer

Boreal Water Collection, Inc. Company Blog

Boreal Water Collection, Inc. News:

Boreal Water Collection Releases Open Letter to Shareholders

Boreal Water Collection to Exhibit at China's Largest Food Show

Boreal Water Collection Reports Continued Growth in the Third Quarter of 2014, Sales Increase by 14% While Profitability Rises by 57%

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.35, up 16.67%, on 2,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 2,876 and its 52-week low/high is $0.06/$0.60.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview

Dominovas Energy Corp. Appoints International Business Professional to Board of Directors

Dominovas Energy and Delphi Sign MOU

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.07, up 7.53%, on 55,800 volume with 6 trades. The stock’s average daily volume over the past 60 days is 18,743, and its 52-week low/high is $0.032/$0.31.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President

MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.457, up 3.86%, on 332,741 volume with 66 trades. The stock’s average daily volume over the past 60 days is 120,252, and its 52-week low/high is $0.3401/$1.00.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Deploys AOT(TM) Viscosity Reduction System on Condensate Pipeline in Eagle Ford

STWA (ZERO) Key Management Featured in Exclusive QualityStocks Interview

STWA (OTCQX: ZERO) Announces Engagement of QualityStocks Investor Relations Services

Start Scientific, Inc. (STSC)

The QualityStocks Daily Newsletter would like to spotlight Start Scientific, Inc. (STSC). Today, Start Scientific, Inc. closed trading at $0.14, up 7.69%, on 600 volume with 1 trade. The stock’s average daily volume over the past 60 days is 28,496, and its 52-week low/high is $0.10/$0.62.

Operating from headquarters in San Antonio, Texas, Start Scientific, Inc. (STSC) is in continual and aggressive pursuit of its corporate objective to take advantage of oil and gas exploration and development opportunities that are overlooked by mid-sized oil and gas companies.

Start Scientific’s is focused on developing leases and/or joint venture partnerships for its four primary projects in Mississippi, Texas, North Dakota and West Virginia. The projects include shallow, deep, and horizontal drilling opportunities. Geographically, the projects offer the company diversity for exploration and drilling.

As a progressive oil exploration, drilling, extraction and delivery company, Start Scientific relies on the vast knowledge of its management team, which provides more than half a century of combined industry experience. Leveraging strong industry contacts established by company founder Norris R. Harris, Start Scientific also explores partnership and joint-venture opportunities to further accelerate its growth.

Supported by a management team highly experienced in the workings of natural resources and business development, Start Scientific is well-positioned to achieve its mission to explore low-risk land lease opportunities on properties with known oil deposits, develop facilities on these properties to cost effectively extract the oil, and to distribute the refined oil for sale in the open market. Disclaimer

Start Scientific, Inc. Company Blog

Start Scientific, Inc. News:

Start Scientific, Inc. Signs Farmout Agreement With Durban Energy

Start Scientific, Inc. Acquires Option to Purchase 1,500 Acres of Leases in Matagorda County, Texas

Start Scientific, Inc. Signs Farmout Agreement for Flora Field, Madison County, Mississippi


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Fortune Stock Alerts




The Stock Psycho

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251